Dual CAR T-cell targeting CD19/Ig-kappa for safer Lymphoma therapy


This new CAR T-cell can be developed to treat children and adults with B cell lymphoma. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or combination treatment with existing first, second, or third line interventions. B cell Lymphoma is a cause of significant morbidity and mortality. The field of immunotherapy represents a market of 100 billion US dollars and is growing steadily.


CAR T cell therapy (autologous or allogeneic) that recognizes malignant B cells expressing IgKappa and CD19 but not IgLambda. This design enables a safer approach to treat B cell lymphoma as it will not deplete all B cells, including the healthy B cells, only the B cells that express IgKappa and CD19.


Our data demonstrates an effective and highly significant reduction in tumour cells when tested for killing malignant B cell lymphoma cells in vitro.


Publication is available here (conference abstract) and here (full paper).


WO2020011706 entered national phase in USA and Europe.


Ingen resultater funnet

Siden du ser etter ble ikke funnet. Prøv å omformulere søket ditt, eller bruk menyen.